In vitro activity of LY333328, an investigational glycopeptide antibiotic, against enterococci and staphylococci

Schwalbe, Richard; McIntosh, Angela C; Qaiyumi, Sadaf; Johnson, Judith A.; Johnson, Rachel; Furness, Kathleen; Holloway, William J.; Steele-Moore, Lynn

doi:10.1128/aac.40.10.2416

Cited by 67 publications

(43 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Oritavancin (Targanta), a semisynthetic glycopeptide derived from a vancomycin analogue, has shown promise against MRSA, as well as potential activity against vancomycinresistant strains of staphylococci and enterococci. 24,25,[80][81][82][83][84][85][86][87] Oritavancin displays concentration-dependent bactericidal activity and has an extended half-life allowing administration every 24 or 48 hours. [88][89][90][91] Oritavancin is currently in Phase III clinical trials, and, although no formally published clinical trials are available, meeting presentations suggest that it is effective in the treatment of skin and softtissue infections.…”

Section: Place In Therapymentioning

confidence: 99%

Telavancin: A novel lipoglycopeptide antimicrobial agent

Attwood

LaPlante

2007

American Journal of Health-System Pharmacy

View full text Add to dashboard Cite

show abstract

Section: Place In Therapymentioning

confidence: 99%

Telavancin: A novel lipoglycopeptide antimicrobial agent

Attwood

LaPlante

2007

American Journal of Health-System Pharmacy

View full text Add to dashboard Cite

show abstract

“…The major advantage of oritavancin over vancomycin, is its good activity against vancomycin-resistant enterococci (E. faecalis and E. faecium). In vitro studies have demonstrated that oritavancin inhibited all VRE strains tested at MIC 90 values of 1 -2 µg/ml and exhibited a prolonged PAE, including strains with a high level of resistance to vancomycin such as 1024 µg/ml [114]. Synergy with ampicillin was demonstrated in 61% of isolates [115].…”

Section: Oritavancinmentioning

confidence: 99%

Investigational treatments for postoperative surgical site infections

Poulakou¹,

Giamarellou²

2007

Expert Opinion on Investigational Drugs

View full text Add to dashboard Cite

Surgical site infections rank third among nosocomial infections, representing a global threat, associated with the emergence of multi-drug-resistant bacteria. The pharmaceutical industry has recently curtailed developmental programmes; however, the need for new compounds is extremely important. This article reviews new antimicrobials and immunointerventional targets for their potential to treat surgical site infections in comparison with recently licensed compounds. Daptomycin, dalbavancin, oritavancin, telavancin, iclaprim and ranbezolid seem to be promising agents against infections caused by Gram-positive pathogens and effectively address the present problems of multi-resistance in Gram-positive infections. Peptide deformylase inhibitors and immunostimulating agents open new perspectives in this field; however, very few compounds targeting Gram-negative problematic pathogens are in the pipeline of the future. Tigecycline (recently marketed) ceftobiprole, ceftaroline and doripenem seem to possess an extended anti-Gram-positive and -negative spectrum. Among these compounds, only doripenem demonstrates activity against Pseudomonas aeruginosa, for which there is a clear unmet need for new compounds, focusing on new targets.

show abstract

“…Oritavancin is also extremely active against Streptococcus spp. Data from earlier and recent in vitro studies are depicted in Table 2 , the shaded area representing assays performed with the inclusion of 0.002% of polysorbate-80 [56,57,[110][111][112][113][114][115][116][117][118][119][120][121][122][123] .…”

Section: Antimicrobial Activitymentioning

confidence: 99%

Oritavancin: a new promising agent in the treatment of infections due to Gram-positive pathogens

Poulakou

Giamarellou

2008

Expert Opinion on Investigational Drugs

View full text Add to dashboard Cite

Nosocomial and community-acquired infections caused by Gram-positive pathogens continue to be a challenge, mainly due to the increasing rates of resistance among Staphylococcus spp. and Enterococcus spp. Oritavancin, a new parenteral semisynthetic glycopeptide, possessing rapid bactericidal action and an antimicrobial spectrum containing all Gram-positive pathogens (streptococci, staphylococci, enterococci--vancomycin-resistant enterococci included--and Clostridia spp.) irrespective of their resistance status to the precursor molecule of vancomycin, is expected to file a new drug application by the first trimester of 2008. Once-daily dosing, good penetration into macrophages, in vitro activity against bacteria embedded in biofilms and low adverse reaction potential are further considered as oritavancin's advantages over existing drugs. While waiting for the results of supplementary Phase III studies to be announced, preliminary reports suggest the new drug will be a welcome addition to the existing antimicrobial armamentarium against Gram-positive cocci.

show abstract

In vitro activity of LY333328, an investigational glycopeptide antibiotic, against enterococci and staphylococci

Cited by 67 publications

References 12 publications

Telavancin: A novel lipoglycopeptide antimicrobial agent

Telavancin: A novel lipoglycopeptide antimicrobial agent

Investigational treatments for postoperative surgical site infections

Oritavancin: a new promising agent in the treatment of infections due to Gram-positive pathogens

Contact Info

Product

Resources

About